<div id="readability-page-1"><p>DBV Technologies (NASDAQ:DBVT - Get Free Report) is projected to post its  Q4 2025 results before the market opens on Friday, April 10th. Analysts expect the company to announce earnings of ($0.1564) per share and revenue of $1.0890 million for the quarter. Investors can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, April 2, 2026 at 7:00 AM ET.</p><div><p><span></span><span>Get <strong>DBV Technologies</strong> alerts:</span></p></div><ul><li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li></ul><p>DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings results on Saturday, February 14th. The company reported ($1.15) earnings per share (EPS) for the quarter. The business had revenue of $0.65 million for the quarter. DBV Technologies had a negative return on equity of 189.17% and a negative net margin of 2,606.83%. On average, analysts expect DBV Technologies to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year. </p><h2>DBV Technologies Price Performance</h2><p>DBV Technologies stock opened at $21.06 on Friday. The stock has a market capitalization of $1.17 billion, a PE ratio of -4.03 and a beta of -0.94. The business has a 50 day simple moving average of $21.49 and a 200-day simple moving average of $17.53. DBV Technologies has a 12 month low of $6.00 and a 12 month high of $26.18. </p><h2>Hedge Funds Weigh In On DBV Technologies</h2><p>Institutional investors and hedge funds have recently bought and sold shares of the business. Ikarian Capital LLC acquired a new stake in  DBV Technologies in the 4th quarter valued at about $10,064,000.  Vestal Point Capital LP purchased a new position in  DBV Technologies in the 4th quarter worth approximately $5,751,000.  Squadron Capital Management LLC acquired a new position in shares of  DBV Technologies during the 4th quarter worth approximately $4,601,000.  Millennium Management LLC grew its position in shares of  DBV Technologies by 89.7% in the fourth quarter. Millennium Management LLC now owns 640,885 shares of the company's stock valued at $12,286,000 after purchasing an additional 303,022 shares in the last quarter.  Finally, Engineers Gate Manager LP purchased a new stake in shares of  DBV Technologies in the fourth quarter valued at approximately $479,000. 71.74% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Analysts Set New Price Targets</h2><p>A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald  set a $48.00 price target on shares of DBV Technologies in a research note on Wednesday, December 17th. HC Wainwright  set a $40.00 price objective on shares of DBV Technologies in a research report on Thursday, December 18th. Citigroup  reaffirmed an &#34;outperform&#34; rating on shares of DBV Technologies in a report on Wednesday, December 17th. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of DBV Technologies in a research report on Monday, December 29th. Finally, Guggenheim  reissued a &#34;buy&#34; rating and set a $51.00 target price on shares of DBV Technologies in a research note on Friday, March 27th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one  has issued  a Hold rating and two have assigned  a Sell rating to the stock. Based on data from MarketBeat, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $38.65.</p><p><b>Check Out Our Latest Research Report on DBVT</b></p><h2>About DBV Technologies</h2> (Get Free Report)<p>DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies. </p><p>The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.</p><h2>Read More</h2><ul><li>Five stocks we like better than DBV Technologies</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REJWVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REJWVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in DBV Technologies Right Now?</h2><p>Before you consider DBV Technologies, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.</p><p>While DBV Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>DBV Technologies (NASDAQ:DBVT) is set to release its Q4 2025 earnings on April 10, with analysts expecting a loss of $0.1564 per share and revenue of $1.089 million. The company reported a loss of $1.15 per share and revenue of $0.65 million in its last quarterly results. Institutional investors hold 71.74% of the stock, and analysts have mixed ratings, with a consensus target price of $38.65. DBV Technologies focuses on developing immunotherapies for allergic diseases, particularly peanut allergies in children.</p>

Market Beat

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Advanced Biomed

Direxion S&P Biotech Bear 3X

DBV Tech

iShares US Medical Devices

SPDR S&P Health Equip

SPDR S&P Biotech

ALPS Medical Breakthrough

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Friday